Roche Holding AG (SWX: ROP)
Health Care · Pharmaceuticals · CH
CHF360.40
+0.73% today · +21.9% 1Y
Roche Holding AG (SWX: ROP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $344.27B and employs 103,249 people.
Over the last twelve months the share price has gained 21.9%, trading between 258.20 and 375.80.
Tweenvest scores Roche Holding AG across four factors: quality 92/100, value 21/100, growth 30/100, dividend 72/100. Its strongest factor is quality.
ROP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $344.27B
- Revenue (TTM)
- $77.92B
- P/E
- 23.33
- EPS
- 15.33
- Dividend yield
- 2.78%
- Beta (5Y)
- 0.33
- 52-week high
- CHF375.80
- 52-week low
- CHF258.20
- Avg volume (3M)
- —
- Shares outstanding
- 796.77M
- Employees
- 103,249
- Next earnings
- —
About Roche Holding AG
Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside a broader international presence. The company's pharmaceutical division is dedicated to developing and marketing a diverse range of medicinal products. These treatments target various therapeutic areas like oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory conditions. Additionally, their portfolio addresses specific ailments such as anemia, cancer, dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. In the diagnostics sector, Roche supplies advanced in-vitro tests utilized for detecting and monitoring a wide array of diseases, including cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. They also provide crucial diagnostic instruments and reagents to healthcare facilities. Furthermore, Roche is engaged in a research partnership with Synlogic, Inc., focused on identifying a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). This well-established organization, founded in 1896, maintains its corporate headquarters in Basel, Switzerland.
- ISIN
- CH1499059983
- Founded
- 1896
- Listed since
- Aug 20, 2003
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.05T | $1,181.87 | +0.22% |
| Johnson & JohnsonNYSE: JNJ | $630.04B | $262.46 | +0.39% |
| Merck & Co., Inc.NYSE: MRK | $359.22B | $144.87 | -0.50% |
| Novartis AGSWX: NOVN | $272.48B | CHF119.10 | +1.17% |
| AstraZeneca PLCLSE: AZN | $246.25B | £119.59 | -0.32% |
| Novo Nordisk A/SCPSE: NOVO B | $169.11B | Dkr255.25 | +2.14% |
| Pfizer Inc.NYSE: PFE | $161.19B | $28.32 | +0.12% |
| Bristol-Myers Squibb CompanyNYSE: BMY | $120.77B | $57.09 | -3.43% |
Figures last refreshed Oct 11, 2026.